Item Type | Name |
Academic Article
|
A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer.
|
Academic Article
|
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
|
Academic Article
|
Silibinin synergizes with mitoxantrone to inhibit cell growth and induce apoptosis in human prostate cancer cells.
|
Academic Article
|
The effect of ultrasonic irradiation on doxorubicin-induced cytotoxicity in three human bladder cancer cell lines.
|
Academic Article
|
Prostate cancer in a man with multiple previous cancers.
|
Academic Article
|
Sarcoidosis in a man with renal carcinoid tumor.
|
Academic Article
|
Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.
|
Academic Article
|
Management of the side effects of androgen deprivation therapy in men with prostate cancer.
|
Academic Article
|
A man with changes in the urinary bladder: benign metaplasia or adenocarcinoma?
|
Academic Article
|
A young woman with multiple kidney lesions.
|
Academic Article
|
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application.
|
Academic Article
|
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.
|
Academic Article
|
Adjuvant medical therapy for prostate cancer.
|
Academic Article
|
A renaissance in the medical treatment of advanced prostate cancer.
|
Academic Article
|
Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.
|
Academic Article
|
Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.
|
Academic Article
|
Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma.
|
Academic Article
|
A rare case of metastatic renal epithelioid angiomyolipoma.
|
Academic Article
|
Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches.
|
Academic Article
|
Prostate cancer: celecoxib trampled in the STAMPEDE trial.
|
Academic Article
|
Increased survival with enzalutamide in prostate cancer after chemotherapy.
|
Academic Article
|
Axitinib, a new therapeutic option in renal cell carcinoma.
|
Academic Article
|
Optimal management of recurrent prostate cancer in older patients.
|
Academic Article
|
Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer.
|
Academic Article
|
Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
|
Academic Article
|
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
|
Academic Article
|
A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
|
Academic Article
|
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
|
Academic Article
|
Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
|
Academic Article
|
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
|
Academic Article
|
High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials.
|
Academic Article
|
Bicalutamide-associated fulminant hepatotoxicity.
|
Academic Article
|
Silibinin suppresses CD44 expression in prostate cancer cells.
|
Academic Article
|
Recurrent urothelial carcinoma with pulmonary metastasis.
|
Academic Article
|
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
|
Academic Article
|
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
|
Academic Article
|
Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
|
Academic Article
|
Abiraterone and increased survival in metastatic prostate cancer.
|
Academic Article
|
Bladder cancer in 2011: the dawn of personalized medicine.
|
Academic Article
|
Redefining hormone sensitive disease in advanced prostate cancer.
|
Academic Article
|
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
|
Academic Article
|
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
|
Academic Article
|
Clinical opportunities and challenges in targeting tumour dormancy.
|
Academic Article
|
Abiraterone in metastatic prostate cancer without previous chemotherapy.
|
Academic Article
|
Targeted therapy in advanced urothelial carcinoma.
|
Academic Article
|
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
|
Concept
|
Urologic Neoplasms
|
Concept
|
Neoplasms, Multiple Primary
|
Concept
|
Brain Neoplasms
|
Concept
|
Lung Neoplasms
|
Concept
|
Neoplasms, Germ Cell and Embryonal
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Urinary Bladder Neoplasms
|
Concept
|
Neoplasms, Complex and Mixed
|
Concept
|
Urogenital Neoplasms
|
Concept
|
Thoracic Neoplasms
|
Concept
|
Neoplasms, Second Primary
|
Concept
|
Cancer Vaccines
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Penile Neoplasms
|
Concept
|
Kidney Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Abdominal Neoplasms
|
Concept
|
Neoplasms, Hormone-Dependent
|
Concept
|
Neoplasms
|
Concept
|
Skin Neoplasms
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Liver Neoplasms
|
Concept
|
Soft Tissue Neoplasms
|
Concept
|
Testicular Neoplasms
|
Academic Article
|
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
|
Academic Article
|
Collision renal cell papillary and medullary carcinoma in a 66-year-old man.
|
Academic Article
|
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research.
|
Academic Article
|
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.
|
Academic Article
|
Sequencing medical therapy in prostate cancer: not as easy as 1-2-3.
|
Academic Article
|
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.
|
Academic Article
|
Functionalized gold nanorods for thermal ablation treatment of bladder cancer.
|
Academic Article
|
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study.
|
Academic Article
|
Metastatic relapse after initial clinical stage I testicular Leydig cell tumor.
|
Academic Article
|
The prognostic significance of Gleason scores in metastatic prostate cancer.
|
Academic Article
|
Geriatric considerations in the treatment of advanced prostate cancer.
|
Academic Article
|
Micropapillary bladder cancer: current treatment patterns and review of the literature.
|
Academic Article
|
Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.
|
Academic Article
|
Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.
|
Academic Article
|
Visceral metastases in prostate cancer: an underestimated and understudied subgroup.
|
Academic Article
|
Pancreatic metastases from renal cell carcinoma treated with stereotactic body radiation therapy.
|
Academic Article
|
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
|
Academic Article
|
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
|
Academic Article
|
Gleason stratifications prognostic for survival in men receiving definitive external beam radiation therapy for localized prostate cancer.
|
Academic Article
|
Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
|
Academic Article
|
Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer.
|
Academic Article
|
Local Control Rates of Metastatic Renal Cell Carcinoma (RCC) to Thoracic, Abdominal, and Soft Tissue Lesions Using Stereotactic Body Radiotherapy (SBRT).
|
Academic Article
|
Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: Is RCC truly radioresistant?
|
Academic Article
|
Upfront Chemotherapy for Metastatic Prostate Cancer.
|
Academic Article
|
The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma.
|
Academic Article
|
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL.
|
Academic Article
|
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
|
Academic Article
|
Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data.
|
Academic Article
|
Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
|
Academic Article
|
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
|
Academic Article
|
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
|
Academic Article
|
Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review?
|
Academic Article
|
Disease and Treatment Characteristics of Men Diagnosed With Metastatic Hormone-Sensitive Prostate Cancer in Real Life: Analysis From a Commercial Claims Database.
|
Academic Article
|
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
|
Academic Article
|
Patient characterization and usage trends of proton beam therapy for localized prostate cancer in the United States: A study of the National Cancer Database.
|
Academic Article
|
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
|
Academic Article
|
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial.
|
Academic Article
|
Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
|
Grant
|
Texas EXperimental Cancer Therapeutics Network - TEX CTN
|
Grant
|
Targeted nanoparticle thermoablation for the treatment of bladder cancer
|
Academic Article
|
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
|
Academic Article
|
The Antineoplastic Activity of Photothermal Ablative Therapy with Targeted Gold Nanorods in an Orthotopic Urinary Bladder Cancer Model.
|
Academic Article
|
Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.
|
Academic Article
|
Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade.
|
Academic Article
|
Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
|
Academic Article
|
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk Factors.
|
Academic Article
|
The Changing Treatment Landscape for Metastatic Urothelial Carcinoma.
|
Academic Article
|
Contribution of bladder cancer pathology assessment in planning clinical trials.
|
Academic Article
|
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.
|
Academic Article
|
Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.
|
Academic Article
|
Point-Prostate Cancer Genomic Analysis: Routine or Research Only?
|
Academic Article
|
Multifunctional nanoclusters of NaYF4:Yb3+,Er3+ upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer.
|
Academic Article
|
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
Academic Article
|
NCCN Guidelines Updates: Management of Muscle-Invasive Bladder Cancer.
|
Academic Article
|
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.
|
Academic Article
|
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
|
Academic Article
|
Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
|
Academic Article
|
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.
|
Academic Article
|
Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
|
Academic Article
|
Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer.
|
Academic Article
|
Review of SWOG S1314: Lessons from a Randomized Phase II Study of Co-Expression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer.
|
Academic Article
|
Prostate Cancer Central Nervous System Metastasis in a Contemporary Cohort.
|
Academic Article
|
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695).
|
Academic Article
|
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
|
Academic Article
|
National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy.
|
Academic Article
|
Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma.
|
Academic Article
|
Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.
|
Academic Article
|
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
|
Academic Article
|
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer.
|
Academic Article
|
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer.
|
Academic Article
|
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
|
Academic Article
|
Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor.
|
Academic Article
|
Patterns of Treatment and Outcomes in Older Men With Penile Cancer: A SEER Dataset Analysis.
|
Academic Article
|
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations.
|
Academic Article
|
Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly.
|
Academic Article
|
NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022.
|
Academic Article
|
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
|
Academic Article
|
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
|
Academic Article
|
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
|
Academic Article
|
Association of Surgical Approach and Urinary Diversion in Radical Cystectomy for Bladder Cancer With Costs and Readmission: Results From a Large Private Health Insurance Cohort.
|
Academic Article
|
A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
|
Academic Article
|
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
|
Academic Article
|
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
|
Academic Article
|
Racial differences in survival for early stage (T1) penile cancer: Analysis from the SEER database.
|
Academic Article
|
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
|
Academic Article
|
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
|
Academic Article
|
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
|
Academic Article
|
Use of Peripheral Intravenous Access in Patients Undergoing Chemotherapy for Testicular Cancer.
|
Academic Article
|
Metabolic and cardiovascular disease risk for Zimbabwean men with prostate cancer receiving long-term androgen deprivation therapy.
|
Academic Article
|
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
|